PubMed Health⌕ Search

Biomedical subjects

D Anselmi

Publications and source records attributed to D Anselmi.

8 recordsLinked to original sources

Nitric oxide reaction with lipid peroxyl radicals spares alpha-tocopherol during lipid peroxidation. Greater oxidant protection from the pair nitric oxide/alpha-tocopherol than alpha-tocopherol/ascorbate.

The reactions of nitric oxide ((.)NO) and alpha-tocopherol (alpha-TH) during membrane lipid oxidation were examined and compared with the pair alpha-TH/ascorbate. Nitric oxide serves as a more potent inhibitor of lipid peroxidation propagation reactions than alpha-TH and protects alpha-TH from oxidation. Mass spectrometry, oxygen and (.)NO consumption, conjugated diene analyses, and alpha-TH fluorescence determinations all demonstrated that (.)NO preferentially reacts with lipid radical species, with alpha-TH consumption not occurring until (.)NO concentrations fell below a critical level. In addition, alpha-TH and (.)NO cooperatively inhibit lipid peroxidation, exhibiting greater antioxidant capacity than the pair alpha-TH/ascorbate. Pulse radiolysis analysis showed no direct reaction between (.)NO and alpha-tocopheroxyl radical (alpha-T(.)), inferring that peroxyl radical termination reactions are the principal lipid-protective mechanism mediated by (.)NO. These observations support the concept that (.)NO is a potent chain breaking antioxidant toward peroxidizing lipids, due to facile radical-radical termination reactions with lipid radical species, thus preventing alpha-TH loss. The reduction of alpha-T(.) by ascorbate was a comparatively less efficient mechanism for preserving alpha-TH than (.)NO-mediated termination of peroxyl radicals, due to slower reaction kinetics and limited transfer of reducing equivalents from the aqueous phase. Thus, the high lipid/water partition coefficient of (.)NO, its capacity to diffuse and concentrate in lipophilic milieu, and a potent reactivity toward lipid radical species reveal how (.)NO can play a critical role in regulating membrane and lipoprotein lipid oxidation reactions.

Amidines↗

[Gastric leiomyoblastomas: a clinical case report].

Leiomyoblastomas are about the 10% of non epithelial gastric neoplasms. They are interesting for clinical, therapeutic and prognostic findings very different in comparison commonest epithelial tumours. The authors, after discussing aetiology, pathogenesis, clinical outline, diagnosis, histological and pathological features as well as therapeutic treatment of these neoplasms, report a case describing diagnostic and therapeutic management.

Aged↗

[Surgical treatment of total rectal prolapse: Delorme's technique].

Rectal total prolapsus is a cause of a permanent disablement more founded in old women. Many pathogenetic hypotheses are made up to date time, many surgical treatments were proposed for the treatments of this disease: through perineal, abdominal or combined way. The results are different, of course, in a short and a long time, whether in the matter of relapse of the prolapse, or in morbidity in connection to surgical treatment and his sequences. After a review of the most frequent techniques now in use, the Authors report their experience on 6 patients operated from 6 January 1988 to June 1993, giving reasons for their preference to Delorme's operation through perineal way.

Adult↗

Tumor markers as targets for selective diagnostic and therapeutic procedures.

Monoclonal antibodies (MAbs) that are reactive with tumor associated antigens (TAAs) have led to many of the recent advances made in tumor immunology. At the present time, many of these MAbs have already been used in various aspects of patient management and in better understanding the biology of carcinoma cell populations. Because of their diversity, specificity and biological activity, these MAbs are potentially ideal agents for a variety of applications in malignant disorders such as, clinical diagnosis using serum assays, immunocytopathological analyses of effusions or fine-needle aspiration specimens, immunoscintigraphy, radioimmunoguided surgery and, with additional development, site directed immunotherapy. Nevertheless, their clinical application shows advantages and limitations. Optimization of their clinical use is actually under evaluation in several Institutions, including our Department. Many innovations have been developed over the last decade which may enhance their clinical efficacy. In this view, an optimal tumor targeting for diagnostic or therapeutic applications may require a better choice of radiotracer, generation of new molecules and the characterization of TAAs at the target level.

Antibodies, Monoclonal↗